• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Artiva Biotherapeutics, Inc. - Common Stock (NQ:ARTV)

    8.540 +0.540 (+6.75%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,432,302
    Open 8.610
    Bid (Size) 8.520 (100)
    Ask (Size) 8.660 (200)
    Prev. Close 8.000
    Today's Range 8.100 - 8.830
    52wk Range 1.470 - 14.53
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +101.9%
    +101.9%
    1 Month
    -19.7%
    -19.7%
    3 Month
    +26.5%
    +26.5%
    6 Month
    +172.0%
    +172.0%
    1 Year
    +335.7%
    +335.7%

    More News

    Read More
    News headline image
    Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
    Via FinancialNewsMedia
    News headline image
    Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Keep an eye on the top gainers and losers in Tuesday's session. ↗
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Via Chartmill
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    Myseum (NASDAQ: MYSE) Realizes $6.8M in Asset Sale – Watch AMCI, ARTV, QIPT, SURG Today!
    Via AB Newswire
    News headline image
    Monday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Which stocks are gapping on Monday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Disease Treated with AlloNK®
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
    From Artiva Biotherapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4 Biotech Stocks Lifting Off As Momentum Builds ↗
    Via Benzinga

    Frequently Asked Questions

    Is Artiva Biotherapeutics, Inc. - Common Stock publicly traded?
    Yes, Artiva Biotherapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Artiva Biotherapeutics, Inc. - Common Stock trade on?
    Artiva Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock?
    The ticker symbol for Artiva Biotherapeutics, Inc. - Common Stock is ARTV on the Nasdaq Stock Market
    What is the current price of Artiva Biotherapeutics, Inc. - Common Stock?
    The current price of Artiva Biotherapeutics, Inc. - Common Stock is 8.540
    When was Artiva Biotherapeutics, Inc. - Common Stock last traded?
    The last trade of Artiva Biotherapeutics, Inc. - Common Stock was at 06/12/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.